ANTIBODY SELECTIVE FOR TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR AND USE THEREOF

• Main Authors: KIMBERLY ROBERT P, ZHOU TONG, KOOPMAN WILLIAM J, ICHIKAWA KIMIHISA
• Format: Patent
• Language: English
• Published: 02.09.2005
• Edition: 7
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; DERIVATIVES THEREOF; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; NUCLEIC ACIDS; NUCLEOSIDES; NUCLEOTIDES; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; SUGARS; VINEGAR; WINE

PROBLEM TO BE SOLVED: To provide an antibody selective for specific TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor DR5 not only binding to cell surface receptor but also strongly inducing apoptosis of various type of idioblasts (including tumor cells) in vivo and in vitro without requiring crosslinking nor solidification, and to provide medicinal compositions and antitumor agents which comprise the antibody as an active ingredient. SOLUTION: The antibody is a purified antibody specifically binding to TRAIL receptor DR5, wherein the antibody (a), in vitro, has, in a soluble form, cell death inducing activity to DR5 expression target cells at ≤1 μg/ml concentration (b), in vivo, has tumoricidal activity to tumor cells expressing DR5, and (c) binds to none of TRAIL receptor DR4, DcR1 and DcR2. COPYRIGHT: (C)2005,JPO&NCIPI